OncoMatch/Clinical Trials/NCT05465174
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
Is NCT05465174 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tovorafenib for craniopharyngioma, child.
Treatment: Tovorafenib — The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Cannot have received: tumor-directed therapy
Newly Diagnosed Participants: Participants should not have undergone any previous tumor-directed therapy.
Cannot have received: RAS-pathway inhibitor
Exception: have not received Tovorafenib will be eligible
Participants should not have previously received any RAS-pathway, but have not received Tovorafenib will be eligible.
Lab requirements
Blood counts
ANC >=1000/mm3; Platelet count >= 100,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Kidney function
Serum creatinine < 1.5 ULN based on age and gender
Liver function
Bilirubin (sum of conjugated + unconjugated) <= 1.5 x ULN for age (except in participants with documented Gilbert syndrome); ALT <= 3 x ULN; Serum albumin >=2 g/dL (20g/L)
Cardiac function
No clinically significant active cardiovascular disease, or history of myocardial infarction, or deep vein thrombosis/pulmonary embolism within 6 months prior to registration, ongoing cardiomyopathy, or current prolonged QTcF interval > 440 ms based on triplicate ECG average
Adequate Bone Marrow Function...Adequate Renal Function...Adequate Liver Function...Adequate Neurologic Function...Adequate Pulmonary Function...PT/PTT/INR within institutional normal limits or deemed appropriate for surgical intervention by the treating team for patients undergoing surgery biopsy/resection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- Rady Children's Hospital/University of California, San Diego · San Diego, California
- University of California, San Francisco · San Francisco, California
- University of Florida · Gainesville, Florida
- Ann & Robert H. Lurie Children's Hospital of Chicago · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify